Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer

Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer

<sup>177</sup>Lu-PSMA-617 radioligand therapy (<sup>177</sup>Lu-PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) currently consists of 4–6 cycles of 6.0–7.4 GBq of <sup>177</sup>Lu-PSMA-617 each every 6–8 weeks. While safety and e...

Full description

Bibliographic Details
Main Authors: Nicolai Mader, Christina Schoeler, Niloufar Pezeshkpour, Konrad Klimek, Daniel Groener, Christian Happel, Nikolaos Tselis, Philipp Mandel, Frank Grünwald, Amir Sabet
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
prostate-specific membrane antigen (PSMA)
<sup>177</sup>Lu-PSMA-617
radioligand therapy (RLT)
intermittent treatment
metastatic castration-resistant prostate cancer (mCRPC)
Online Access:https://www.mdpi.com/2072-6694/15/18/4605

Internet

https://www.mdpi.com/2072-6694/15/18/4605

Similar Items